ABT-431, a D1 receptor agonist prodrug, has efficacy in Parkinson's disease

Annals of Neurology

Volumn 45, Issue 6, 1999, Pages 736-741

  Rascol, O ^a,f   Blin, O ^b   Thalamas, C ^a   Descombes, S ^a   Soubrouillard, C ^b   Azulay, P ^b   Fabre, N ^a   Viallet, F ^c   Lafnitzegger, K ^d   Wright, S ^d   Carter, J H ^e   Nutt, J G ^e  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b Ctr Pharmacologie Clin d'E   (France)

^c Department of Neurology ^*  (France)

^d ABBOTT LABORATORIES   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f Lab de Pharmacologie Med et Clin   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADROGOLIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DYSKINESIA; FEMALE; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PRODRUGS; PYRIDINES; TETRAHYDRONAPHTHALENES;

EID: 0033019985     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8249(199906)45:6<736::AID-ANA7>3.0.CO;2-F     Document Type: Article

References (25)

1. Kebabian JW, Calne DB. Multiple receptors for dopamine. Nature 1979;277:93-96
2. Bedard PJ, Gomez-Mancilla B, Blanchet P, et al. Dopamine receptor families and the treatment of Parkinson's disease. Clin Neuropharmacol 1995;18(Suppl 1):S178-S187
3. Chase TN, Verhagen Metman L, Bravi D, et al. Dopamine-receptor subtype-selective agonists in the treatment of Parkinson's disease. Clin Neuropharmacol 1995;18(Suppl 1):S207-S215
4. Calne DB. Treatment of Parkinson's disease. N Engl J Med 1993;329:1021-1027
5. Braun A, Fabbrini G, Mouradian MM, et al. Selective D1 dopamine receptor agonist treatment of Parkinson's disease. J Neural Transm 1987;68:41-50
6. Nomoto M, Jenner P, Marsden CD. The dopamine D2 agonist LY-141865, but not the D1 agonist SKF-38393, reverses parkinsonism induced by MPTP in the common marmoset. Neurosci Lett 1985;57:37-41
7. Falardeau P, Bouchard S, Bedard PJ, et al. Behavioural and biochemical effect of chronic treatment with D1 and/or D2 dopamine agonists in MPTP monkeys. Eur J Pharmacol 1988;150: 59-66
8. Kebabian JW, Britton DR, DeNinno MP, et al. A-77636: a potent and selective dopamine D1 receptor agonist with anti-parkinsonian activity in marmosets. Eur J Pharmacol 1992;229: 203-209
9. Temlett J, Chong P, Oertel W, et al. The D1 dopamine receptor partial agonist CY 208-243, exhibits antiparkinsonian activity in the MPTP-treated marmoset. Eur J Pharmacol 1988;156: 197-206
10. Temlett J, Quinn N, Jenner PGJ, et al. Anti-parkinsonian activity of CY 208-243, a partial D-1 dopamine receptor agonist, in MPTP-treated marmosets and patients with Parkinson's disease. Mov Disord 1989;4:261-265
11. Emre M, Rinne UK, Rascol A, et al. Effects of a selective partial D1 agonist, CY 208-243 in de novo patients with Parkinson's disease. Mov Disord 1992;7:239-243
12. Shiosaki K, Jenner P, Asin KE, et al. ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease. J Pharmacol Exp Ther 1996;276: 150-160
13. Michaelides MR, Hong Y, DiDomenico SD Jr, et al. ([(-)-trans-9, 10-hydroxy-2-propyl-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-azacyclopent-1- ena[c]phenanthrene-hydtochloride (A-86929): a potent and selective D1 dopamine receptor agonist that maintains behavioural efficacy following repeated administration, and characterization of its diacetyl prodrug, ABT-431. J Med Chem 1995;38:3445-3447
14. Grondin R, Bedard PJ, Britton DR, Shiosaki K. Potential therapeutic use of the selective D1 receptor agonist A-86929: an acute study in parkinsonian levodopa-primed monkeys. Neurology 1997;49:421-426
15. Asin KE, Domino EF, Nikkel A, Shiosaki K. The selective dopamine D1 receptor agonist A-86929 maintains efficacy with repeated treatment in rodent and animal primate models of Parkinson's disease. J Pharmacol Exp Ther 1997;281:454-459
16. Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-752
17. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442
18. Fahn S, Elton R, Members of UPDRS Development Committee. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent developments in Parkinson's disease, vol 2. Florham Park, NJ: Macmillan Health Care Information, 1987: 153-163
19. Nelson MV, Berchow RC, Lewitt PA, et al. Pharmacokinetic and pharmacodynamic modelling of L-dopa plasma concentrations and clinical effects in Parkinson's disease after Sinemet. Clin Neuropharmacol 1989;12:91-97
20. Hodges JL, Lehmann EL. Hodges-Lehmann estimators. In: Kotz S, Johnson NL, eds. Encyclopedia of statistical sciences. New York; John Wiley, 1983:642-645
21. Nutt JG. Levodopa induced dyskinesia: review, observations and speculations. Neurology 1990;40:340-345
22. Gomez-Mancilla B, Bedard PJ. Effect of D1 and D2 agonists and antagonists on dyskinesia produced by L-DOPA in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys. J Pharmacol Exp Ther 1991;259:409-413
23. Bennett JP, Landow ER, Schuh LA. Suppression of dyskinesias in advanced Parkinson's disease. Neurology 1993;43:1551-1555
24. Lokhandwala MF, Barrett RJ. Dopamine receptor agonists in cardiovascular therapy. Drug Dev Res 1983;3:299-310
25. Sabouni MH, Alkadhi KA, Lokhandwala MF. Pharmacological characterisation of dopamine receptors in the stellate ganglia with selective DA1 and DA2 receptor agonists and antagonists. J Pharmacol Exp Ther 1986;236:65-70